Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151737 | 0.86 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1RECQL | |
| SCHEMBL13992410 | 0.83 | KMT2A (0.45) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL2520866 | 0.82 | RECQL (0.47) | MEN1KMT2AHTTL3MBTL1RECQL | |
| Bromide SCHEMBL10777741 | 0.82 | RECQL (0.47) | MEN1KMT2AHTTL3MBTL1RECQL | |
| SCHEMBL8908481 | 0.81 | RIPK1 (0.50) | MEN1KMT2ARECQLRIPK1NPC1 | |
| SCHEMBL22009525 | 0.80 | MEN1 (0.45) | MEN1KMT2AHTTL3MBTL1RECQL | |
| SCHEMBL16889019 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AHTTL3MBTL1RECQL | |
| SCHEMBL5962473 | 0.79 | TSHR (0.54) | MEN1KMT2AHTTL3MBTL1RIPK1 | |
| SCHEMBL13992431 | 0.78 | ALOX5 (0.46) | — | |
| SCHEMBL13539071 | 0.78 | ALDH1A1 (0.48) | MEN1KMT2AHTTL3MBTL1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256639-A1 | PEPTOID NEUTRALIZING AGENTS | UNIV CALIFORNIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256638-A1 | PEPTOID NEUTRALIZING AGENTS | UNIV CALIFORNIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | NEW YORK UNIVERSITY | 2009-12-24 | — | — | US | disclosed |
| WO-2009139922-A2 | PEPTOID COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7462592-B2 | Compositions and methods for polynucleotide delivery | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | ZUCKERMANN RONALD N | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256638-A1 | PEPTOID NEUTRALIZING AGENTS | SERPINC1, ANTXR2, VIP | MEN1 1890/4885KMT2A 4567/4885HTT 1876/4885 |
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | POLN, RNASE1, NCL | MEN1 1701/4885KMT2A 3308/4885HTT 149/4885 |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | PEPD, NGLY1, ANPEP | MEN1 2363/4885KMT2A 4664/4885HTT 3658/4885 |
| US-20140256639-A1 | PEPTOID NEUTRALIZING AGENTS | SERPINC1, ANTXR2, VIP | MEN1 1890/4885KMT2A 4567/4885HTT 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.